SSS17
Phase 2Small molecule
SSS17 is one of 74 small molecule programs targeting Phase 1. It is currently in Phase 2.
2
Indications
6
Total Trials
2
Active Trials
73
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
75 competitors in Anemia
#DrugCompanyPhaseTrials
1Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Kenalog
BBausch Health Americas, Inc.
Approved
Rayos
RRoxane Laboratories
Approved
Orgovyx
Sumitomo Pharma America, Inc.Approved
Leustatin
EMD SeronoApproved
Rituxan
RochePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
Imbruvica
PPharmacyclics LLC.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Anemia2 trials
Phase 12 trials
Tics1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SSS17. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details